Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer

Breast Cancer Research

Volumn 10, Issue 4, 2008, Pages

  Akkiprik, Mustafa ^a   Feng, Yumei ^b,c   Wang, Huamin ^d   Chen, Kexin ^b   Hu, Limei ^d   Sahin, Aysegul ^d   Krishnamurthy, Savitri ^d   Ozer, Ayse ^a   Hao, Xishan ^b,c   Zhang, Wei ^d  

^a MARMARA UNIVERSITY   (Turkey)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 5;

ANIMAL; BREAST TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; METABOLISM; METHODOLOGY; MOUSE; ONCOLOGY; PATHOLOGY; PROGNOSIS; PROTEIN TERTIARY STRUCTURE; REVIEW;

ANIMALS; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MEDICAL ONCOLOGY; MICE; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; TRANSCRIPTION, GENETIC;

EID: 65449142983     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2116     Document Type: Review

References (147)

1. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002, 23:824-854.
2. Beattie J, Allan GJ, Lochrie JD, Flint D. Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J 2006, 395:1-19. 1409685, 16526944.
3. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999, 20:761-787.
4. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995, 16:3-34.
5. Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001, 54:133-137. 1187050, 11376123.
6. Kim JJ, Accili D. Signalling through IGF-I and insulin receptors: where is the specificity?. Growth Horm IGF Res 2002, 12:84-90.
7. Renehan AG, Harvie M, Howell A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer 2006, 13:273-278.
8. Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer 2001, 8:197-209.
9. Hao X, Sun B, Hu L, Lahdesmaki H, Dunmire V, Feng Y, Zhang SW, Wang H, Wu C, Wang H, Fuller GN, Symmans WF, Shmulevich I, Zhang W. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 2004, 100:1110-1122.
10. Morgan DO, Edman JC, Standring DN, Fried VA, Smith MC, Roth RA, Rutter WJ. Insulin-like growth factor II receptor as a multifunctional binding protein. Nature 1987, 329:301-307.
11. Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol 2002, 175:19-31.
12. Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ, Weber MM, Wolf E. Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter?. Cancer Res 2001, 61:8601-8610.
13. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004, 363:1346-1353.
14. Li X, Cao X, Li X, Zhang W, Feng Y. Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer. Cancer Sci 2007, 98:1592-1596.
15. Zhu X, Ling N, Shimasaki S. Cloning of the rat insulin-like growth factor binding protein-5 gene and DNA sequence analysis of its promoter region. Biochem Biophys Res Commun 1993, 190:1045-1052.
16. Allander SV, Larsson C, Ehrenborg E, Suwanichkul A, Weber G, Morris SL, Bajalica S, Kiefer MC, Luthman H, Powell DR. Characterization of the chromosomal gene and promoter for human insulin-like growth factor binding protein-5. J Biol Chem 1994, 269:10891-10898.
17. Ehrenborg E, Larsson C, Stern I, Janson M, Powell DR, Luthman H. Contiguous localization of the genes encoding human insulin-like growth factor binding proteins 1 (IGBP1) and 3 (IGBP3) on chromosome 7. Genomics 1992, 12:497-502.
18. Kalus W, Zweckstetter M, Renner C, Sanchez Y, Georgescu J, Grol M, Demuth D, Schumacher R, Dony C, Lang K, Holak TA. Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions. EMBO J 1998, 17:6558-6572. 1171003, 9822601.
19. Imai Y, Moralez A, Andag U, Clarke JB, Busby WH, Clemmons DR. Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and -5 markedly reduce IGF-I binding and alter their biologic actions. J Biol Chem 2000, 275:18188-18194.
20. Conover CA, Kiefer MC. Regulation and biological effect of endogenous insulin-like growth factor binding protein-5 in human osteoblastic cells. J Clin Endocrinol Metab 1993, 76:1153-1159.
21. Ständker L, Wobst P, Mark S, Forssmann WG. Isolation and characterization of circulating 13-kDa C-terminal fragments of human insulin-like growth factor binding protein-5. FEBS Lett 1998, 441:281-286.
22. Coverley JA, Baxter RC. Phosphorylation of insulin-like growth factor binding proteins. Mol Cell Endocrinol 1997, 128:1-5.
23. Clemmons DR, Busby W, Clarke JB, Parker A, Duan C, Nam TJ. Modifications of insulin-like growth factor binding proteins and their role in controlling IGF actions. Endocr J 1998, 45(Suppl):S1-S8.
24. Bunn RC, Fowlkes JL. Insulin-like growth factor binding protein proteolysis. Trends Endocrinol Metab 2003, 14:176-181.
25. Busby WH, Nam TJ, Moralez A, Smith C, Jennings M, Clemmons DR. The complement component C1s is the protease that accounts for cleavage of insulin-like growth factor-binding protein-5 in fibroblast medium. J Biol Chem 2000, 275:37638-37644.
26. Thrailkill KM, Quarles LD, Nagase H, Suzuki K, Serra DM, Fowlkes JL. Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. Endocrinology 1995, 136:3527-3533.
27. Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM. ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 2000, 278:511-515.
28. Overgaard MT, Boldt HB, Laursen LS, Sottrup-Jensen L, Conover CA, Oxvig C. Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase. J Biol Chem 2001, 276:21849-21853.
29. Conover CA, Perry JE, Tindall DJ. Endogenous cathepsin D-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. J Clin Endocrinol Metab 1995, 80:987-993.
30. Radulescu RT. Nuclear localization signal in insulin-like growth factor-binding protein type 3 [abstract]. Trends Biochem Sci 1994, 19:278.
31. Schedlich LJ, Young TF, Firth SM, Baxter RC. Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J Biol Chem 1998, 273:18347-18352.
32. Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA, Baxter RC. Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit. J Biol Chem 2000, 275:23462-23470.
33. Jurgeit A, Berlato C, Obrist P, Ploner C, Massoner P, Schmölzer J, Haffner MC, Klocker H, Huber LA, Geley S, Doppler W. Insulin-like growth factor-binding protein-5 enters vesicular structures but not the nucleus. Traffic 2007, 8:1815-1828.
34. Abrass CK, Berfield AK, Andress DL. Heparin binding domain of insulin-like growth factor binding protein-5 stimulates mesangial cell migration. Am J Physiol 1997, 273:F899-F906.
35. Allan GJ, Tonner E, Szymanowska M, Shand JH, Kelly SM, Phillips K, Clegg RA, Gow IF, Beattie J, Flint DJ. Cumulative mutagenesis of the basic residues in the 201-218 region of insulin-like growth factor (IGF)-binding protein-5 results in progressive loss of both IGF-I binding and inhibition of IGF-I biological action. Endocrinology 2006, 147:338-349.
36. Shemer J, Yaron A, Werner H, Shao ZM, Sheikh MS, Fontana JA, LeRoith D, Roberts CT. Regulation of insulin-like growth factor (IGF) binding protein-5 in the T47D human breast carcinoma cell line by IGF-I and retinoic acid. J Clin Endocrinol Metab 1993, 77:1246-1250.
37. Kou K, Jenkins NA, Gilbert DJ, Copeland NG, Rotwein P. Organization, expression, and chromosomal location of the mouse insulin-like growth factor binding protein 5 gene. Genomics 1994, 20:412-418.
38. Kou K, Mittanck DW, Fu C, Rotwein P. Structure and function of the mouse insulin-like growth factor binding protein 5 gene promoter. DNA Cell Biol 1995, 14:241-249.
39. Duan C, Clemmons DR. Transcription factor AP-2 regulates human insulin-like growth factor binding protein-5 gene expression. J Biol Chem 1995, 270:24844-24851.
40. McCarthy TL, Casinghino S, Mittanck DW, Ji CH, Centrella M, Rotwein P. Promoter-dependent and -independent activation of insulin-like growth factor binding protein-5 gene expression by prostaglandin E2 in primary rat osteoblasts. J Biol Chem 1996, 271:6666-6671.
41. Gabbitas B, Pash JM, Delany AM, Canalis E. Cortisol inhibits the synthesis of insulin-like growth factor-binding protein-5 in bone cell cultures by transcriptional mechanisms. J Biol Chem 1996, 271:9033-9038.
42. Ji C, Chen Y, Centrella M, McCarthy TL. Activation of the insulin-like growth factor-binding protein-5 promoter in osteoblasts by cooperative E box, CCAAT enhancer-binding protein, and nuclear factor-1 deoxyribonucleic acid-binding sequences. Endocrinology 1999, 140:4564-4572.
43. Yeh LC, Adamo ML, Duan C, Lee JC. Osteogenic protein-1 regulates insulin-like growth factor-I (IGF-I), IGF-II, and IGF-binding protein-5 (IGFBP-5) gene expression in fetal rat calvaria cells by different mechanisms. J Cell Physiol 1998, 175:78-88.
44. Yeh LC, Lee JC. Identification of an osteogenic protein-1 (bone morphogenetic protein-7)-responsive element in the promoter of the rat insulin-like growth factor-binding protein-5 gene. Endocrinology 2000, 141:3278-3286.
45. Tanno B, Negroni A, Vitali R, Pirozzoli MC, Cesi V, Mancini C, Calabretta B, Raschellà G. Expression of insulin-like growth factor-binding protein 5 in neuroblastoma cells is regulated at the transcriptional level by c-Myb and B-Myb via direct and indirect mechanisms. J Biol Chem 2002, 277:23172-23180.
46. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev 2001, 81:1269-1304.
47. Cesi V, Giuffrida ML, Vitali R, Tanno B, Mancini C, Calabretta B, Raschellà G. C/EBP alpha and beta mimic retinoic acid activation of IGFBP-5 in neuroblastoma cells by a mechanism independent from binding to their site. Exp Cell Res 2005, 305:179-189.
48. Higo H, Duan C, Clemmons DR, Herman B. Retinoic acid inhibits cell growth in HPV negative cervical carcinoma cells by induction of insulin-like growth factor binding protein-5 (IGFBP-5) secretion. Biochem Biophys Res Commun 1997, 239:706-709.
49. Dong Y, Canalis E. Insulin-like growth factor (IGF) I and retinoic acid induce the synthesis of IGF-binding protein 5 in rat osteoblastic cells. Endocrinology 1995, 136:2000-2006.
50. Hwa V, Oh Y, Rosenfeld RG. Insulin-like growth factor binding protein-3 and -5 are regulated by transforming growth factor-beta and retinoic acid in the human prostate adenocarcinoma cell line PC-3. Endocrine 1997, 6:235-242.
51. Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1989, 1:188-191.
52. Darwish HM, DeLuca HF. Recent advances in the molecular biology of vitamin D action. Prog Nucleic Acid Res Mol Biol 1996, 53:321-344.
53. Rozen F, Yang XF, Huynh H, Pollak M. Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation. J Natl Cancer Inst 1997, 89:652-656.
54. Twigg SM, Baxter RC. Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit. J Biol Chem 1998, 273:6074-6079.
55. Twigg SM, Kiefer MC, Zapf J, Baxter RC. Insulin-like growth factor-binding protein-5 complexes with the acid-labile subunit. J Biol Chem 1998, 273:28791-28798.
56. Arai T, Arai A, Busby WH, Clemmons DR. Glycosaminoglycans inhibit degradation of insulin-like growth factor-binding protein-5. Endocrinology 1994, 135:2358-2363.
57. Arai T, Parker A, Busby W, Clemmons DR. Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes. J Biol Chem 1994, 269:20388-20393.
58. Beattie J, Phillips K, Shand JH, Szymanowska M, Flint DJ, Allan GJ. Molecular recognition characteristics in the insulin-like growth factor (IGF)-insulin-like growth factor binding protein-3/5 (IGFBP-3/5) heparin axis. J Mol Endocrinol 2005, 34:163-175.
59. Xu Q, Yan B, Li S, Duan C. Fibronectin binds insulin-like growth factor-binding protein 5 and abolishes its ligand-dependent action on cell migration. J Biol Chem 2004, 279:4269-4277.
60. Nam TJ, Busby WH, Rees C, Clemmons DR. Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth. Endocrinology 2000, 141:1100-1106.
61. Amaar YG, Thompson GR, Linkhart TA, Chen ST, Baylink DJ, Mohan S. Insulin-like growth factor-binding protein-5 (IGFBP-5) interacts with a four and a half LIM protein 2 (FHL2). J Biol Chem 2002, 277:12053-12060.
62. Nam TJ, Busby W, Clemmons DR. Insulin-like growth factor-binding protein-5 binds to plasminogen activator inhibitor-I. Endocrinology 1997, 138:2972-2978.
63. Nam T, Moralez A, Clemmons D. Vitronectin binding to IGF binding protein-5 (IGFBP-5) alters IGFBP-5 modulation of IGF-I actions. Endocrinology 2002, 143:30-36.
64. Hyde C, Hollier B, Anderson A, Harkin D, Upton Z. Insulin-like growth factors (IGF) and IGF-binding proteins bound to vit-ronectin enhance keratinocyte protein synthesis and migration. J Invest Dermatol 2004, 122:1198-1206.
65. Amaar YG, Baylink DJ, Mohan S. Ras-association domain family 1 protein, RASSF1C, is an IGFBP-5 binding partner and a potential regulator of osteoblast cell proliferation. J Bone Miner Res 2005, 20:1430-1439.
66. Jones JI, Gockerman A, Busby WH, Camacho-Hubner C, Clemmons DR. Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Cell Biol 1993, 121:679-687. 2119570, 7683690.
67. Bramani S, Song H, Beattie J, Tonner E, Flint DJ, Allan GJ. Amino acids within the extracellular matrix (ECM) binding region (201-218) of rat insulin-like growth factor binding protein (IGFBP)-5 are important determinants in binding IGF-I. J Mol Endocrinol 1999, 23:117-123.
68. Song H, Beattie J, Campbell IW, Allan GJ. Overlap of IGF- and heparin-binding sites in rat IGF-binding protein-5. J Mol Endocrinol 2000, 24:43-51.
69. Twigg SM, Kiefer MC, Zapf J, Baxter RC. A central domain binding site in insulin-like growth factor binding protein-5 for the acid-labile subunit. Endocrinology 2000, 141:454-457.
70. Moralez AM, Maile LA, Clarke J, Busby WH, Clemmons DR. Insulin-like growth factor binding protein-5 (IGFBP-5) interacts with thrombospondin-1 to induce negative regulatory effects on IGF-I actions. J Cell Physiol 2005, 203:328-334.
71. Kricker JA, Towne CL, Firth SM, Herington AC, Upton Z. Structural and functional evidence for the interaction of insulin-like growth factors (IGFs) and IGF binding proteins with vitronectin. Endocrinology 2003, 144:2807-2815.
72. Hadsell DL, Bonnette SG, Lee AV. Genetic manipulation of the IGF-I axis to regulate mammary gland development and function. J Dairy Sci 2002, 85:365-377.
73. Neuenschwander S, Schwartz A, Wood TL, Roberts CT, Hennighausen L, LeRoith D. Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest 1996, 97:2225-2232. 507301, 8636401.
74. Wood TL, Yee D. IGFs and IGFBPs in the normal mammary gland and in breast cancer. J Mammary Gland Biol Neoplasia 2000, 5:1-5.
75. Flint DJ, Tonner E, Allan GJ. Insulin-like growth factor binding proteins: IGF-dependent and -independent effects in the mammary gland. J Mammary Gland Biol Neoplasia 2000, 5:65-73.
76. Marshman E, Green KA, Flint DJ, White A, Streuli CH, Westwood M. Insulin-like growth factor binding protein 5 and apoptosis in mammary epithelial cells. J Cell Sci 2003, 116:675-682.
77. Tonner E, Quarrie L, Travers M, Barber M, Logan A, Wilde C, Flint D. Does an IGF-binding protein (IGFBP) present in involuting rat mammary gland regulate apoptosis?. Prog Growth Factor Res 1995, 6:409-414.
78. Tonner E, Barber MC, Travers MT, Logan A, Flint DJ. Hormonal control of insulin-like growth factor-binding protein-5 production in the involuting mammary gland of the rat. Endocrinology 1997, 138:5101-5107.
79. Tonner E, Barber MC, Allan GJ, Beattie J, Webster J, Whitelaw CB, Flint DJ. Insulin-like growth factor binding protein-5 (IGFBP-5) induces premature cell death in the mammary glands of transgenic mice. Development 2002, 129:4547-4557.
80. Sutherland KD, Lindeman GJ, Visvader JE. The molecular culprits underlying precocious mammary gland involution. J Mammary Gland Biol Neoplasia 2007, 12:15-23.
81. Baxter FO, Neoh K, Tevendale MC. The beginning of the end: death signaling in early involution. J Mammary Gland Biol Neoplasia 2007, 12:3-13.
82. Marshman E, Streuli CH. Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function. Breast Cancer Res 2002, 4:231-239. 137936, 12473169.
83. Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K, Akira S, Clarke AR, Watson CJ. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 1999, 13:2604-2616. 317074, 10521404.
84. Lochrie JD, Phillips K, Tonner E, Flint DJ, Allan GJ, Price NC, Beattie J. Insulin-like growth factor binding protein (IGFBP)-5 is upregulated during both differentiation and apoptosis in primary cultures of mouse mammary epithelial cells. J Cell Physiol 2006, 207:471-479.
85. Ning Y, Hoang B, Schuller AG, Cominski TP, Hsu MS, Wood TL, Pintar JE. Delayed mammary gland involution in mice with mutation of the insulin-like growth factor binding protein 5 gene. Endocrinology 2007, 148:2138-2147.
86. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 1997, 99:1478-1483. 507966, 9119990.
87. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 2004, 100:499-506.
88. Wu Y, Mohamed H, Chillar R, Ali I, Clayton S, Slamon D, Vadgama JV. Clinical significance of Akt and HER2/neu over-expression in African American and Latina women with breast cancer: a retrospective cohort study. Breast Cancer Res 2008, 10:R3. 2374954, 18184439.
89. Leal SM, Huang SS, Huang JS. Interactions of high affinity insulin-like growth factor-binding proteins with the type V transforming growth factor-beta receptor in mink lung epithelial cells. J Biol Chem 1999, 274:6711-6717.
90. Garner CP, Ding YC, John EM, Ingles SA, Olopade OI, Huo D, Adebamowo C, Ogundiran T, Neuhausen SL. Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent. Hum Genet 2008, 123:247-255.
91. Pekonen F, Nyman T, Ilvesmäki V, Partanen S. Insulin-like growth factor binding proteins in human breast cancer tissue. Cancer Res 1992, 52:5204-5207.
92. McGuire SE, Hilsenbeck SG, Figueroa JA, Jackson JG, Yee D. Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. Cancer Lett 1994, 77:25-32.
93. Huynh H. In vivo regulation of the insulin-like growth factor system of mitogens by human chorionic gonadotropin. Int J Oncol 1998, 13:571-575.
94. Van 't Veer LJ, Dai H, Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
95. Nishidate T, Katagiri T, Lin ML, Mano Y, Miki Y, Kasumi F, Yoshimoto M, Tsunoda T, Hirata K, Nakamura Y. Genome-wide gene expression profiles of breast cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int J Oncol 2004, 25:797-819.
96. Mita K, Zhang Z, Ando Y, Toyama T, Hamaguchi M, Kobayashi S, Hayashi S, Fujii Y, Iwase H, Yamashita H. Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer. Jpn J Clin Oncol 2007, 37:575-582.
97. Miyake H, Pollak M, Gleave ME. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 2000, 60:3058-3064.
98. Stolf BS, Carvalho AF, Martins WK, Runza FB, Brun M, Hirata R, Jordão Neves E, Soares FA, Postigo-Dias J, Kowalski LP, Reis LF. Differential expression of IGFBP-5 and two human ESTs in thyroid glands with goiter, adenoma and papillary or follicular carcinomas. Cancer Lett 2003, 191:193-202.
99. Becker M, Sommer A, Kratzschmar JR, Seidel H, Pohlenz HD, Fichtner I. Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther 2005, 4:151-168.
100. Tokunaga E, Kimura Y, Oki E, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Baba H, Maehara Y. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 2006, 118:284-289.
101. Tokunaga E, Kataoka A, Kimura Y, Oki E, Mashino K, Nishida K, Koga T, Morita M, Kakeji Y, Baba H, Ohno S, Maehara Y. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer 2006, 42:629-635.
102. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005, 11:865s-870s.
103. Akkiprik M, Nicorici D, Cogdell D, Jia YJ, Hategan A, Tabus I, Yli-Harja O, Y D, Sahin A, Zhang W. Dissection of signaling pathways in fourteen breast cancer cell lines using reverse-phase protein lysate microarray. Technol Cancer Res Treat 2006, 5:543-551.
104. Perks CM, Bowen S, Gill ZP, Newcomb PV, Holly MP. Differential IGF-independent effects of insulin-like growth factor binding proteins (1-6) on apoptosis of breast epithelial cells. J Cell Biochem 1999, 75:652-664.
105. Perks CM, McCaig C, Clarke JB, Clemmons DR, Holly JM. Effects of a non-IGF binding mutant of IGFBP-5 on cell death in human breast cancer cells. Biochem Biophys Res Commun 2002, 294:995-1000.
106. Wang H, Arun BK, Wang H, Fuller GN, Zhang W, Middleton LP, Sahin AA. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J 2008, 14:261-267.
107. Butt AJ, Dickson KA, McDougall F, Baxter RC. Insulin-like growth factor binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem 2003, 278:29676-29685.
108. Butt AJ, Dickson KA, Jambazov S, Baxter RC. Enhancement of tumor necrosis factor-alpha-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells. Endocrinology 2005, 146:3113-3122.
109. McCaig C, Perks CM, Holly JM. Signaling pathways involved in the direct effects of IGFBP-5 on breast epithelial cell attachment and survival. J Cell Biochem 2002, 84:784-794.
110. McCaig C, Perks CM, Holly JM. Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J Cell Sci 2002, 115:4293-4303.
111. Dupont J, Le Roith D. Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol Pathol 2001, 54:149-154. 1187053, 11376126.
112. Helle SI. The insulin-like growth factor system in advanced breast cancer. Best Pract Res Clin Endocrinol Metab 2004, 18:67-79.
113. Lee AV, Weng CN, Jackson JG, Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 1997, 152:39-47.
114. Salerno M, Sisci D, Mauro L, Guvakova MA, Ando S, Surmacz E. Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells. Int J Cancer 1999, 81:299-304.
115. Bartucci M, Morelli C, Mauro L, Andò S, Surmacz E. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res 2001, 61:6747-6754.
116. Huynh H, Yang XF, Pollak M. A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780. Cell Growth Differ 1996, 7:1501-1506.
117. Parisot JP, Leeding KS, Hu XF, DeLuise M, Zalcberg JR, Bach LA. Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line. Breast Cancer Res Treat 1999, 55:231-242.
118. Coutts A, Murphy LJ, Murphy LC. Expression of insulin-like growth factor binding proteins by T-47D human breast cancer cells: regulation by progestins and antiestrogens. Breast Cancer Res Treat 1994, 32:153-164.
119. Pratt SE, Pollak MN. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res 1993, 53:5193-5198.
120. Figueroa JA, Jackson JG, McGuire WL, Krywicki RF, Yee D. Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. J Cell Biochem 1993, 52:196-205.
121. Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, Perrone F, . NCI-Naple Breast Cancer Group Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005, 12:721-747. NCI-Naple Breast Cancer Group.
122. Matsumoto T, Gargosky SE, Kelley K, Rosenfeld RG. Characterization of an insulin-like growth factor binding protein-5 protease produced by rat articular chondrocytes and a neuroblastoma cell line. Growth Regul 1996, 6:185-190.
123. Tanno B, Cesi V, Vitali R, Sesti F, Giuffrida ML, Mancini C, Calabretta B, Raschellà G. Silencing of endogenous IGFBP-5 by micro RNA interference affects proliferation, apoptosis and differentiation of neuroblastoma cells. Cell Death Differ 2005, 12:213-223.
124. Cesi V, Vitali R, Tanno B, Giuffrida ML, Sesti F, Mancini C, Raschellà G. Insulin-like growth factor binding protein 5: contribution to growth and differentiation of neuroblastoma cells. Ann N Y Acad Sci 2004, 1028:59-68.
125. Tanno B, Vitali R, De Arcangelis D, Mancini C, Eleuteri P, Dominici C, Raschellà G. Bim-dependent apoptosis follows IGFBP-5 down-regulation in neuroblastoma cells. Biochem Biophys Res Commun 2006, 351:547-552.
126. Gregory CW, Kim D, Ye P, D'Ercole AJ, Pretlow TG, Mohler JL, French FS. Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft. Endocrinology 1999, 140:2372-2381.
127. Arnold JT, Le H, McFann KK, Blackman MR. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Am J Physiol Endocrinol Metab 2005, 288:E573-E584.
128. Matilainen M, Malinen M, Saavalainen K, Carlberg C. Regulation of multiple insulin-like growth factor binding protein genes by 1α,25-dihydroxyvitamin D3. Nucleic Acids Res 2005, 33:5521-5532. 1236724, 16186133.
129. Xu C, Graf LF, Fazli L, Coleman IM, Mauldin DE, Li D, Nelson PS, Gleave M, Plymate SR, Cox ME, Torok-Storb BJ, Knudsen BS. Regulation of global gene expression in the bone marrow microenvironment by androgen: androgen ablation increases insulin-like growth factor binding protein-5 expression. Prostate 2007, 67:1621-1629.
130. Kanzaki S, Hilliker S, Baylink DJ, Mohan S. Evidence that human bone cells in culture produce insulin-like growth factor-binding protein-4 and -5 proteases. Endocrinology 1994, 134:383-392.
131. Slootweg MC, Ohlsson C, van Elk EJ, Netelenbos JC, Andress DL. Growth hormone receptor activity is stimulated by insulin-like growth factor binding protein 5 in rat osteosarcoma cells. Growth Regul 1996, 6:238-246.
132. Schneider MR, Zhou R, Hoeflich A, Krebs O, Schmidt J, Mohan S, Wolf E, Lahm H. Insulin-like growth factor-binding protein-5 inhibits growth and induces differentiation of mouse osteosarcoma cells. Biochem Biophys Res Commun 2001, 288:435-442.
133. Mohan S, Thompson GR, Amaar YG, Hathaway G, Tschesche H, Baylink DJ. ADAM-9 is an insulin-like growth factor binding protein-5 protease produced and secreted by human osteoblasts. Biochemistry 2002, 41:15394-15403.
134. Yin P, Xu Q, Duan C. Paradoxical actions of endogenous and exogenous insulin-like growth factor-binding protein-5 revealed by RNA interference analysis. J Biol Chem 2004, 279:32660-32666.
135. Amaar YG, Tapia B, Chen ST, Baylink DJ, Mohan S. Identification and characterization of novel IGFBP5 interacting protein: evidence IGFBP5-IP is a potential regulator of osteoblast cell proliferation. Am J Physiol Cell Physiol 2006, 290:C900-C906.
136. Govoni KE, Amaar YG, Kramer A, Winter E, Baylink DJ, Mohan S. Regulation of insulin-like growth factor binding protein-5, four and a half lim-2, and a disintegrin and metalloprotease-9 expression in osteoblasts. Growth Horm IGF Res 2006, 16:49-56.
137. Hofmann J, Wegmann B, Hackenberg R, Kunzmann R, Schulz KD, Havemann K. Production of insulin-like growth factor binding proteins by human ovarian carcinoma cells. J Cancer Res Clin Oncol 1994, 120:137-142.
138. Wang H, Rosen DG, Wang H, Fuller GN, Zhang W, Liu J. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol 2006, 19:1149-1156.
139. Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP. Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin Cancer Res 2007, 13:1438-1444.
140. Miyatake T, Ueda Y, Nakashima R, Yoshino K, Kimura T, Murata T, Nomura T, Fujita M, Buzard GS, Enomoto T. Down-regulation of insulin-like growth factor binding protein-5 (IGFBP-5): novel marker for cervical carcinogenesis. Int J Cancer 2007, 120:2068-2077.
141. Gao XQ, Han JX, Huang HY, Song B, Zhu B, Song CZ. Effect of NS398 on metastasis-associated gene expression in a human colon cancer cell line. World J Gastroenterol 2005, 11:4337-4343.
142. Fenton JI, Lavigne JA, Perkins SN, Liu H, Chandramouli GV, Shih JH, Hord NG, Hursting SD. Microarray analysis reveals that leptin induces autocrine/paracrine cascades to promote survival and proliferation of colon epithelial cells in an Apc genotype-dependent fashion. Mol Carcinog 2008, 47:9-21.
143. Cheung C, Vesey D, Cotterill A, Douglas M, Gobe G, Nicol D, Johnson D. Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas. Int J Urol 2005, 12:17-28.
144. Takahashi M, Papavero V, Yuhas J, Kort E, Kanayama HO, Kagawa S, Baxter RC, Yang XJ, Gray SG, Teh BT. Altered expression of members of the IGF-axis in clear cell renal cell carcinoma. Int J Oncol 2005, 26:923-931.
145. Liu Y, Sun W, Zhang K, Zheng H, Ma Y, Lin D, Zhang X, Feng L, Lei W, Zhang Z, Guo S, Han N, Tong W, Feng X, Gao Y, Cheng S. Identification of genes differentially expressed in human primary lung squamous cell carcinoma. Lung Cancer 2007, 56:307-317.
146. Yi HK, Hwang PH, Yang DH, Kang CW, Lee DY. Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells. Eur J Cancer 2001, 37:2257-2263.
147. Johnson SK, Dennis RA, Barone GW, Lamps LW, Haun RS. Differential expression of insulin-like growth factor binding protein-5 in pancreatic adenocarcinomas: identification using DNA microarray. Mol Carcinog 2006, 45:814-827.